• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白细胞介素-2和环孢素A对支原体肺炎病理特征的影响。

Effects of interleukin-2 and cyclosporin A on pathologic features in Mycoplasma pneumonia.

作者信息

Tanaka H, Honma S, Abe S, Tamura H

机构信息

Third Department of Internal Medicine, Sapporo Medical University School of Medicine, Japan.

出版信息

Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1908-12. doi: 10.1164/ajrccm.154.6.8970385.

DOI:10.1164/ajrccm.154.6.8970385
PMID:8970385
Abstract

To elucidate the immunopathologic mechanisms of Mycoplasma pneumonia, the effects of interleukin-2 (IL-2) and cyclosporin A (CYA) on Mycoplasma pneumonia in mice were investigated. Mice were intranasally inoculated with Mycoplasma pulmonis (M. pul) and treated with IL-2, CYA, or minocycline (MINO) every day between Days 3 and 9. They were killed at Days 7, 14, or 21 after the inoculation. Cell-mediated immunity (CMI) of the host was assessed by delayed-type hypersensitivity (DTH) to sheep red blood cells (SRBC). Peribronchial and perivascular lymphocyte cuffing and the accumulation of macrophages at the ends of bronchioles were exacerbated (p < 0.05) in IL-2-treated mice at Day 14 and reduced (p < 0.05) in CYA-treated mice at Day 7. Although the DTH responses to SRBC of saline-inoculated, IL-2-treated mice were increased at Days 7 (p < 0.01) and 14 (p < 0.05), those of M. pul-inoculated, IL-2-treated mice at Day 7 could not recover to the control level. The CMI levels of M. pul-inoculated, CYA-treated mice were decreased at Days 7, 14 (p < 0.05), and 21 (p < 0.01). Mycoplasma organisms in the lung showed the greatest decrease (p < 0.05) in MINO- and IL-2-treated mice, but increased at Day 21 (p < 0.05) in mice treated with IL-2 alone. These results suggest that the pathologic features of Mycoplasma pneumonia could be modified by the degree of host CMI.

摘要

为阐明支原体肺炎的免疫病理机制,研究了白细胞介素-2(IL-2)和环孢素A(CYA)对小鼠支原体肺炎的影响。将小鼠经鼻接种肺支原体(M. pul),并在第3天至第9天每天用IL-2、CYA或米诺环素(MINO)进行治疗。在接种后第7天、14天或21天处死小鼠。通过对绵羊红细胞(SRBC)的迟发型超敏反应(DTH)评估宿主的细胞介导免疫(CMI)。在第14天,IL-2治疗的小鼠支气管周围和血管周围淋巴细胞套叠以及细支气管末端巨噬细胞的积聚加剧(p<0.05),而在第7天,CYA治疗的小鼠则减少(p<0.05)。尽管在第7天(p<0.01)和第14天(p<0.05),接种生理盐水并经IL-2治疗的小鼠对SRBC的DTH反应增强,但接种M. pul并经IL-2治疗的小鼠在第7天的反应未能恢复到对照水平。接种M. pul并经CYA治疗的小鼠在第7天、14天(p<0.05)和21天(p<0.01)的CMI水平降低。肺中的支原体在MINO和IL-2治疗的小鼠中减少最多(p<0.05),但仅用IL-2治疗的小鼠在第21天增加(p<0.05)。这些结果表明,宿主CMI的程度可改变支原体肺炎的病理特征。

相似文献

1
Effects of interleukin-2 and cyclosporin A on pathologic features in Mycoplasma pneumonia.白细胞介素-2和环孢素A对支原体肺炎病理特征的影响。
Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1908-12. doi: 10.1164/ajrccm.154.6.8970385.
2
[Pathological changes by the imbalance of host T helper lymphocyte subsets in Mycoplasma pulmonis pneumonia of mice].
Kansenshogaku Zasshi. 1998 Apr;72(4):342-6. doi: 10.11150/kansenshogakuzasshi1970.72.342.
3
Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.新型肽脱甲酰基酶抑制剂LBM415(NVP PDF-713)治疗实验性肺炎支原体肺炎的评估
Antimicrob Agents Chemother. 2005 Oct;49(10):4128-36. doi: 10.1128/AAC.49.10.4128-4136.2005.
4
[Protective immune responses induced by intranasal immunization with Mycoplasma pneumoniae P1C-IL-2 fusion DNA vaccine in mice].肺炎支原体P1C-IL-2融合DNA疫苗经鼻内免疫小鼠诱导的保护性免疫反应
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Jun;29(6):585-8.
5
Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.在肺炎支原体下呼吸道感染小鼠模型中,塞托霉素(ABT - 773)治疗对微生物学、组织学、免疫学和呼吸指标的影响
Antimicrob Agents Chemother. 2004 Aug;48(8):2897-904. doi: 10.1128/AAC.48.8.2897-2904.2004.
6
Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.白细胞介素-12基因敲除小鼠感染肺炎支原体后,呼吸道感染导致细菌清除改善和肺部炎症减轻。
Infect Immun. 2007 Jan;75(1):236-42. doi: 10.1128/IAI.01249-06. Epub 2006 Oct 30.
7
[Therapeutic effectiveness of prednisolone in Mycoplasma pulmonis-infected pneumonia in mice].[泼尼松龙对小鼠肺支原体感染性肺炎的治疗效果]
Nihon Kyobu Shikkan Gakkai Zasshi. 1994 Jan;32(1):42-7.
8
Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic profile.鼠肺炎支原体肺炎模型中细胞因子和趋化因子水平升高及肺气流阻力延长:微生物学、组织学、免疫学和呼吸体积描记特征
Infect Immun. 2001 Jun;69(6):3869-76. doi: 10.1128/IAI.69.6.3869-3876.2001.
9
Immunological analysis and pathological examination of gnotobiotic mice monoassociated with Mycoplasma pneumoniae.与肺炎支原体单联的悉生小鼠的免疫学分析及病理学检查
J Med Microbiol. 2009 Jun;58(Pt 6):697-705. doi: 10.1099/jmm.0.007872-0.
10
Intranasal interleukin-12 therapy inhibits Mycoplasma pneumoniae clearance and sustains airway obstruction in murine pneumonia.鼻内白细胞介素-12治疗可抑制小鼠肺炎中肺炎支原体的清除并维持气道阻塞。
Infect Immun. 2008 Feb;76(2):732-8. doi: 10.1128/IAI.00878-07. Epub 2007 Nov 26.

引用本文的文献

1
Evaluating the role of interleukin-2 and interleukin-12 in pediatric patients with concurrent and Epstein-Barr virus infections.评估白细胞介素-2和白细胞介素-12在同时感染巨细胞病毒和爱泼斯坦-巴尔病毒的儿科患者中的作用。
World J Clin Cases. 2024 Aug 16;12(23):5346-5353. doi: 10.12998/wjcc.v12.i23.5346.
2
Dilemma of immunosuppression and infection risk in systemic lupus erythematosus.系统性红斑狼疮中免疫抑制与感染风险的困境。
Rheumatology (Oxford). 2023 Mar 29;62(Suppl 1):i22-i29. doi: 10.1093/rheumatology/keac678.
3
The Correlation between Chest X-ray Scores and the Clinical Findings in Children and Adults with Mycoplasma pneumoniae Pneumonia.
儿童和成人支原体肺炎患者胸部X线评分与临床发现的相关性
Intern Med. 2017 Nov 1;56(21):2845-2849. doi: 10.2169/internalmedicine.8500-16. Epub 2017 Sep 25.
4
Pneumonia, Acute Respiratory Distress Syndrome, and Early Immune-Modulator Therapy.肺炎、急性呼吸窘迫综合征与早期免疫调节剂治疗
Int J Mol Sci. 2017 Feb 11;18(2):388. doi: 10.3390/ijms18020388.
5
Correlation between Radiological and Pathological Findings in Patients with Mycoplasma pneumoniae Pneumonia.肺炎支原体肺炎患者影像学与病理结果的相关性
Front Microbiol. 2016 May 11;7:695. doi: 10.3389/fmicb.2016.00695. eCollection 2016.
6
A common immunopathogenesis mechanism for infectious diseases: the protein-homeostasis-system hypothesis.传染病的一种常见免疫发病机制:蛋白质稳态系统假说。
Infect Chemother. 2015 Mar;47(1):12-26. doi: 10.3947/ic.2015.47.1.12. Epub 2015 Mar 30.
7
Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications.肺炎支原体肺炎发病机制的新观点及治疗意义
Front Microbiol. 2014 Aug 11;5:410. doi: 10.3389/fmicb.2014.00410. eCollection 2014.
8
Mycoplasma pneumoniae pneumonia in children.儿童支原体肺炎
Korean J Pediatr. 2012 Feb;55(2):42-7. doi: 10.3345/kjp.2012.55.2.42. Epub 2012 Feb 14.
9
Fatal Mycoplasma pneumoniae pneumonia in a previously healthy 18-year-old girl.一名既往健康的18岁女孩患致命性肺炎支原体肺炎。
Wien Klin Wochenschr. 2007;119(11-12):379-84. doi: 10.1007/s00508-007-0810-7.
10
Significant role of interleukin-8 in pathogenesis of pulmonary disease due to Mycoplasma pneumoniae infection.白细胞介素-8在肺炎支原体感染所致肺部疾病发病机制中的重要作用。
Clin Diagn Lab Immunol. 2001 Sep;8(5):1028-30. doi: 10.1128/CDLI.8.5.1028-1030.2001.